-
1 Comment
Tibet Cheezheng Tibetan Medicine Co., Ltd is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 9.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
Tibet Cheezheng Tibetan Medicine Co., Ltd's total revenue sank by 6.7% to $403M since the same quarter in the previous year.
Its net income has increased by 16.2% to $103M since the same quarter in the previous year.
Finally, its free cash flow fell by 217.1% to $-143M since the same quarter in the previous year.
Based on the above factors, Tibet Cheezheng Tibetan Medicine Co., Ltd gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | CNY |
| ISIN | CNE100000FM9 |
| Dividend Yield | 1.9% |
|---|---|
| Beta | 0.7 |
| Market Cap | 13B |
| PE Ratio | 22.15 |
| Target Price | None |
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China. It provides products in the areas of orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, and cerebrovascular sectors. The company was founded in 1995 and is based in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. is a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002287.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
